Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SunHo Bio Starts China Trials of Immunocytokine for Solid Tumor Cancers

publication date: Jul 26, 2023

Nanjing SunHo BioPharma has started China Phase I/II trials of a B7H3-IL10 immunocytokine as a potential first-in-class therapy to treat locally advanced or metastatic solid tumors. Immunocytokines are antibody-cytokine fusion proteins designed to localize on tumor lesions and activate anticancer immunity at the disease site. IBB0979 was developed by SunHo using its proprietary Armed ImmunoCytokine platform. SunHo is developing a portfolio of 20 novel immunocytokines and bifunctional antibody fusion proteins for cancer immunotherapy and autoimmune diseases – six of them in clinical trials and three more under IND review. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital